TICKERNERD
Menu
BYAHBYAHConsumer Defensive · Household & Personal Products

BYAH Stock Forecast: Park Ha Biological Technology Co. Ltd. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$2.36
−5.22% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 23 Oct 2026 — in the weakest quartile.

Market cap
$46.0M
Ticker Nerd rank
22/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−1.3%
1M
−6.3%
YTD
−96.3%
1Y
−98.4%
From 52W high
−98.5%
From 52W low
+7.3%
$2
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BYAH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Park Ha Biological Technology Co. Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
82
Growth
78
Revisions
25
Momentum
21
Quality
14
Issuance
12
Value
10
Volatility
8

Size (94): Smaller than most of the companies we track.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYAH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYAH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26BYAH

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BYAH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

BYAH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Park Ha Biological Technology Co. Ltd. returned −98.4% against +15.6% for the S&P 500, dividends included.

BYAH vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26BYAHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BYAH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Park Ha Biological Technology Co. Ltd. (BYAH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
17.6×

Cheaper than 9% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
0.8×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
1.5%

Higher than 31% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−76.5%

Higher than 15% of US stocks

Net margin
−214.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−113.0%

Higher than 12% of US stocks

Return on assets
−50.7%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Park Ha Biological Technology Co. Ltd. (BYAH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Park Ha Biological Technology Co. Ltd. has a market value of $46.0M and an enterprise value of −$4.0M.

  • Shares outstanding: 677,488.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Park Ha Biological Technology Co. Ltd. employs 41 people.

market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

BYAH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
BYAHPark Ha Biological Technology Co. Ltd.$46.0M22
BIOTInstinct Bio Technical Co. Holdings, Inc.$4.0M9
TANHTantech Holdings Ltd.$11.8M18
ATTTAtlas Trinity Tech Ltd.$14.0M7
DSYBig Tree Cloud Holdings Ltd.$27.6M4
UGUnited-Guardian, Inc.$30.6M89
GROVGrove Collaborative Holdings, Inc.$44.1M90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Park Ha Biological Technology Co. Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYAH news & analysis

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH

GlobeNewsWire · 28 Sept 2026negative

Levi & Korsinsky has reminded BYAH shareholders of a lead plaintiff deadline of September 28, 2026 in a lawsuit against Park Ha Biological Technology Co., Ltd. The lawsuit alleges BYAH structured its IPO with a public float of under 5% of the company, a structure it contends enabled coordinated price manipulation before BYAH shares fell 93% in a single session.

Why it matters — BYAH watchers may want to note the active securities lawsuit and its September 2026 lead plaintiff deadline, which centres on allegations tied to the company's IPO structure and a sharp share-price decline.

PHH, BYAH Deadline: PHH, BYAH Investors with Losses in Excess of $100K Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit

PRNewsWire · 21 Sept 2026negative

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Park Ha Biological Technology Co., Ltd. securities that they have an opportunity to lead a securities lawsuit. The notice targets BYAH investors with losses in excess of $100,000 ahead of a deadline.

Why it matters — A securities class-action lawsuit reminder signals potential legal and financial exposure for BYAH that shareholders following the company would want to track.

FAQ

Frequently asked questions about BYAH stock

How does Ticker Nerd's model rank BYAH?

As at 23 Oct 2026, Park Ha Biological Technology Co. Ltd. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the BYAH stock forecast for 2030?

No analyst covering Park Ha Biological Technology Co. Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYAH are extrapolating price history, which says nothing about the business.

How has BYAH stock performed over the past year?

Park Ha Biological Technology Co. Ltd. returned -98.4% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Park Ha Biological Technology Co. Ltd. do?

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products.

What is the latest news on BYAH?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH". Levi & Korsinsky has reminded BYAH shareholders of a lead plaintiff deadline of September 28, 2026 in a lawsuit against Park Ha Biological Technology Co., Ltd. The lawsuit alleges BYAH structured its IPO with a public float of under 5% of the company, a structure it contends enabled coordinated price manipulation before BYAH shares fell 93% in a single session.

Company

About Park Ha Biological Technology Co. Ltd.

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products. The company develops and sells private-label skincare offerings under the Park Ha brand, serving consumers in China through direct product sales and franchise-related channels. Its business also includes franchise services and complementary after-sales beauty services provided through directly operated and franchised locations. Park Ha Biological Technology operates as a holding company with a consumer-focused model centered on personal care and beauty products. The Class A Ordinary Shares provide exposure to a business positioned within the household and personal care segment of the broader consumer market.

CEO Ms. Xiaoqiu Zhang · 41 employees · China · https://parkha.cn